The search for genes that cause or contribute to Parkinson's disease (PD) has intensified since the discovery of alpha-synuclein gene and parkin gene mutations linked to patients with familial Parkinson's disease. NURR1 {the human homolog of roden nurr1), a member of the nuclear receptor super family, may be relevant to the disease since the gene is essential for induction and maintenance of nigra dopaminergic (DAergic) adenotype and heterozygous nurr1 knock-out mice display many features of parkinsonism with aging. To investigate if NURR1 is a susceptibility gene in Parkinson's disease we have performed a case-control study in over 200 PD patients. We have identified two novel variants in NURR1 gene (-291T deletion and -245T ->G substitution) in 10 of 107 proband familial Parkinson's disease (fPD), but not in sporadic PD (sPD, n=94) and age-and race-matched normal controls (NC, n=221). In pedigree analysis of the ten fPD families we have found that all PD patients but none of the non-PD family members have the NURR1 gene variations. A linkage study using 5 haplotype markers in 4 available fPD families suggested that at least two distinct haplotyes exist in these fPD families. Furthermore, we have constructed full-length human NURR1 gene encoding the two variants and demonstrated that the variant genes reduced NURR1 gene expression by >85% when transfected in human embryonic kidney cells HEK293 or in human neuroblastoma cells SH-5YSY. In addition, rate-limited DA synthesis enzyme tyrosine hydroxylase mRNA was significantly low in the SH-5YSY cells transfected with two variant genes. These data suggest that the variants in the NURR1 gene might be PD-related mutations. We, therefore, hypothesize that diminished expression of the NURR1 gene (loss of function), induced by the mutations in the gene, predisposing to DAergic neuron dysfunction, may represents a potentially important risk factor for Parkinson's disease. To test this hypothesis, we propose to study the relationship between the genotype of the mutations and the phenotype of the disease, and to investigate the underlying mechanisms.
First (Aim 1), we will assay for the mutations, genotypes, and phenotypes in the first-degree members of all 10 fPD patients with the identified NURR1 mutations to determine the haplotype linkage, relationship between genotype and phenotype.
Second (Aim 2), we will investigate if the mutations in NURR1 gene are specific for Parkinson's disease by analyzing the gene mutations in a total of 400 NC, 300 sPD, and 120 non-PD neurological disorders. Finally (Aim 3), we will determine the mechanisms by which the mutant genes alter NURR1 expression and DAergic neuronal dysfunction. The proposed experiments, which will take approximately four years for completion, will be conducted in parallel with a pilot study to generate a mouse model carrying the NURR1 mutations. The outcomes of the proposed study will improve our understanding of the role of NURR1 gene in the pathogenesis of Parkinson's disease, and may lead to potential therapeutic interventions, as well as means for diagnosing individuals having an increased risk of developing the disease.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS043567-02
Application #
6710651
Study Section
Special Emphasis Panel (ZRG1-BDCN-3 (01))
Program Officer
Murphy, Diane
Project Start
2003-04-01
Project End
2007-03-31
Budget Start
2004-04-01
Budget End
2005-03-31
Support Year
2
Fiscal Year
2004
Total Cost
$285,950
Indirect Cost
Name
Baylor College of Medicine
Department
Neurology
Type
Schools of Medicine
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Le, Weidong; Pan, Tianhong; Huang, Maosheng et al. (2008) Decreased NURR1 gene expression in patients with Parkinson's disease. J Neurol Sci 273:29-33
Zhu, Wen; Xie, Wenjie; Pan, Tianhong et al. (2008) Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration. J Neurochem 105:1970-8
Pan, Tianhong; Kondo, Seiji; Zhu, Wen et al. (2008) Neuroprotection of rapamycin in lactacystin-induced neurodegeneration via autophagy enhancement. Neurobiol Dis 32:16-25
Pan, Tianhong; Zhu, Wen; Zhao, Hongru et al. (2008) Nurr1 deficiency predisposes to lactacystin-induced dopaminergic neuron injury in vitro and in vivo. Brain Res 1222:222-9
Deng, Hao; Le, Wei-Dong; Jankovic, Joseph (2008) Genetic study of an American family with DYT3 dystonia (lubag). Neurosci Lett 448:180-3
Zhu, Wen; Xie, Wenjie; Pan, Tianhong et al. (2007) Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators. FASEB J 21:3835-44
Deng, Hao; Le, Weidong; Huang, Maosheng et al. (2007) Genetic analysis of LRRK2 P755L variant in Caucasian patients with Parkinson's disease. Neurosci Lett 419:104-7
Zhao, Hongru; Zhu, Wen; Pan, Tianhong et al. (2007) Spinal cord dopamine receptor expression and function in mice with 6-OHDA lesion of the A11 nucleus and dietary iron deprivation. J Neurosci Res 85:1065-76
Deng, Hao; Le, Weidong; Jankovic, Joseph (2007) Genetics of essential tremor. Brain 130:1456-64
Deng, Hao; Le, Wei-Dong; Hunter, Christine B et al. (2007) A family with Parkinson disease, essential tremor, bell palsy, and parkin mutations. Arch Neurol 64:421-4

Showing the most recent 10 out of 24 publications